12:00 AM
 | 
May 14, 2012
 |  BC Week In Review  |  Company News  |  Sales & Marketing

Desitin, Pozen sales and marketing update

Desitin received exclusive rights to develop and commercialize Pozen's migraine drug MT 400 in the EU, Switzerland and Norway. Pozen will receive $500,000 up front and is eligible for $2.5 million in pre-commercialization...

Read the full 151 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >